List price versus net price: what national lists show, and what they leave out

Two prices for every product

The list price is the published, official price: the ex-factory price in a national list, the reimbursement price in a tariff, the maximum price in a cap. The net price is what changes hands after everything that is not published. For many branded medicines the gap is now large, and for some it is most of the price.

What fills the gap

Confidential rebates and managed-entry agreements. Payers agree a public list price and a private discount, sometimes simple (a percentage), sometimes conditional (on volume, on outcomes, on budget caps). The list price is what gets referenced abroad; the discount is what the payer actually pays. This is the single largest component for new branded products in most European markets.

Statutory rebates and clawbacks. Industry-wide schemes return a share of sales to the payer: the UK’s voluntary scheme payments on branded sales, Germany’s statutory manufacturer rebate, Italy’s payback, and similar mechanisms elsewhere. They apply on top of the list price without changing it.

Tender prices. Hospital medicines and, in some countries, outpatient generics are bought by tender at prices that are often not published, or published only as awards. The list price for a tendered product can be a formality.

Wholesale and pharmacy discounts. Below the regulated margins, manufacturers and wholesalers discount to win volume, especially on generics; in the UK the Drug Tariff reimbursement price for generics is set by surveying those actual purchase prices, which is why it tracks the market rather than any list.

Parallel trade itself. Where a parallel import undercuts the domestic pack, the effective price in the destination falls without the list changing.

Where the gap is largest

New, high-value branded products under managed-entry agreements; hospital products bought by tender; and markets with strong statutory rebates. The gap is smallest for mature generics in markets with reference pricing, where competition has already driven the list price close to the transaction price.

Working with published prices anyway

List prices remain the only prices that are systematically public, and they are what the law, the reference-pricing systems and most contracts refer to. The approach is to be explicit about which price a number is and what it is being used for.

• For external reference pricing and launch sequencing, the list price is the right price, because it is what other payers will see.
• For parallel trade, the list price bounds the opportunity; the net price in the exporting country, discovered by asking, decides it.
• For procurement, the list price is the ceiling and the published margins say how far below it a supplier can go; the rest is negotiation.
• For forecasting, model list and net separately and expect the gap to widen for branded products and narrow for generics over a product’s life.

What this means for a price database

A database can only hold what is published. Its value is in holding it correctly: the right rung, the right date, the right currency, with history, so that the published price can be trusted as a benchmark even when the transaction price is private. That is the standard MPA’s prices dataset is built to, and the source reference on each record is there so that the benchmark can be checked.